AT A GLANCE

A new post hoc analysis of phase 3 ECZTRA trials explores the impact of coexisting atopic conditions on treatment outcomes with tralokinumab in moderate-to-severe atopic dermatitis, revealing consistent efficacy and safety across patient subgroups.

Atopic dermatitis (AD) often presents as part of a broader atopic spectrum, with comorbid conditions such as asthma, allergic rhinitis, food allergy, and allergic conjunctivitis reflecting shared type 2 inflammatory pathways. This analysis evaluated whether these atopic comorbidities influence clinical response to tralokinumab, a monoclonal antibody that specifically targets interleukin-13, a central cytokine in AD pathogenesis.

Using pooled data from four placebo-controlled ECZTRA trials (1, 2, 3, and 6), researchers compared treatment responses among adult and adolescent patients with and without atopic comorbidities at baseline. Despite having more severe disease initially, patients with atopic comorbidities achieved comparable week-16 improvements in both EASI-75 and IGA 0/1 scores when treated with tralokinumab versus placebo. The safety profile remained favorable across all subgroups, with most adverse events rated mild to moderate.

These findings reinforce the therapeutic potential of tralokinumab in complex AD populations, suggesting that coexisting atopic diseases do not diminish treatment response. By addressing IL-13–driven inflammation directly, tralokinumab offers a targeted and consistent benefit in patients representing the broader clinical spectrum of AD.

Reference: Paller AS, Soong W, Boguniewicz M, et al. Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. Ann Allergy Asthma Immunol. 2025 Oct;135(4):425-433.e4. doi: 10.1016/j.anai.2025.06.022. Epub 2025 Jun 22. PMID: 40555305.

DRUG AT A GLANCE

ADBRY^® (tralokinumab-ldrm) is a fully human monoclonal antibody developed by LEO Pharma that selectively neutralizes interleukin-13 (IL-13), a key cytokine in the inflammatory cascade of atopic dermatitis. Approved for the treatment of moderate-to-severe AD in adults and adolescents aged 12 years and older, tralokinumab-ldrm has demonstrated significant improvements in skin clearance, itch reduction, and quality of life. Its targeted mechanism allows for effective disease control without broad immunosuppression, making it a leading biologic in type 2–driven dermatologic conditions.